Inhibitory Activity of Synthetic Peptide Antibiotics on Feline Immunodeficiency Virus Infectivity In Vitro

Abstract

for up to 7 days, The virions from the D4E1-treated culture had impaired infectivity, as measured by the 50% tissue culture infectious dose and nested PCR analysis of proviral DNA. However, these noninfectious virions were able to bind and internalize, suggesting a defect at some postentry step. After chronically infected CrFK cells were treated with D4E1 for 24 h, increased cell-associated mature p26 Gag and decreased extracellular virus-associated p26 Gag were observed by Western blot analysis, suggesting that virus assembly and/or release may be blocked by D4E1 treatment, whereas virus binding, penetration, RNA synthesis, and protein synthesis appear to be unaffected. Synthetic peptide antibiotics may be useful tools in the search for antiviral drugs having a wide therapeutic window for host cells.

Preferential Feline Immunodeficiency Virus (FIV) Infection of CD4+CD25+T-Regulatory Cells Correlates both with Surface Expression of CXCR4 and Activation of FIV Long Terminal Repeat Binding Cellular Transcriptional Factors

“…FIV binding and entry assays were performed as described previously (27). Briefly, for viral binding, 10 6 purified CD4 ϩ CD25 ϩ and CD4 ϩ CD25 Ϫ cells were chilled on ice for 20 min followed by incubation with FIV-NCSU 1 for 1 h on ice.…”

Novel Therapeutic Approach for Inhibition of HIV-1 Using Cell-Penetrating Peptide and Bacterial Toxins

“…Previously, a peptide of 17 amino acids has been shown to inhibit FIV production by 50%, and impairs infection of CrFK cells, measured by reduction in reverse transcriptase activity [ 21 ]. To increase peptide stability, we synthesized an identical peptide with an additional Methionine at its N-terminus.…”

“…Nevertheless, no reports investigated the synergistic effects of toxins and therapeutic peptides Here, we report the activity of an 18 amino acid cationic synthetic peptide on production and infection of two strains of HIV-1 pseudoviruses (DH12 and SF162), in human cell lines. This peptide has an identical sequence to a peptide previously shown to neutralize Feline Immunodeficiency Virus (FIV) [ 21 ], except for an additional Methionine at its N-terminus, and is currently investigated in development of plant-based therapeutic approach against HIV-1 [ 22 ]. Additionally, we examined possible synergistic activity of the oligomeric toxins and toxoids from enterotoxigenic E. coli , with the peptide, in blocking HIV-1 production and infection.…”

Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction

“…Subsequently, the fusion peptide is exposed to insert into the target cell membrane, resulting in fusion between the cell membrane and viral envelope, which allow the virus genome to enter the target cells . Based on this process, fusioninhibitory peptides have been successfully developed, or under advance clinical trial for various viruses, such as T-20 for HIV-1, C-peptides (P-400 and P cr -400) for human T-cell leukemia virus, and D4E1 for feline immunodeficiency virus (Kilby et al, 1998;Ma et al, 2002;Pinon et al, 2003). Recently, this strategy of utilizing peptides that block membrane fusion has been applied in SARS-CoV.…”